According to the authors, the research opens up new possibilities for developing the next generation of ChE inhibitors that ...

Tim-3 is an immune checkpoint molecule involved in immunity and inflammation recently linked to late-onset Alzheimer's ...

Biomarker and cognitive data supported treatment with the anti-amyloid agent lecanemab (Leqembi) for up to 36 months in early ...

It wasn't that long ago that the only way to test for Alzheimer's disease was to perform an autopsy on someone who had been ...

Delve into how the biotech industry is pivoting from the amyloid hypothesis to find new Alzheimer's disease treatments.

In animal models, NU-9 was found to show promise in treating Alzheimer's by reducing toxic protein buildup and brain inflammation.

As the Trump administration makes cuts to federal health agencies, some Alzheimer's experts are worried about the impact on ...

Experimental drug NU-9—a small molecule compound approved by the U.S. Food and Drug Administration (FDA) for clinical trials ...

A new blood test identifies a key biomarker for Alzheimer’s disease, which may help make assessing the presence and stage of ...

A new blood test test could determine how far Alzheimer's has progressed and could also help confirm whether another ...

W ith two new treatments for Alzheimer’s disease approved in recent years, there’s growing hope for people at risk of the ...

Knight says that the method of transmission that Collinge identified is “extremely unusual,” and there’s no evidence that ...